Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr−/− murine model of autoimmune lymphoproliferative syndrome (ALPS)-Reference-Cited by-同舟云学术

Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr−/− murine model of autoimmune lymphoproliferative syndrome (ALPS)

Published:2009-04 Issue:4 Volume:37 Page:487-494
ISSN:0301-472X
Container-title:Experimental Hematology
language:en
Short-container-title:Experimental Hematology

Author:

Dowdell Kennichi C.,Pesnicak Lesley,Hoffmann Victoria,Steadman Kenneth,Remaley Alan T.,Cohen Jeffrey I.,Straus Stephen E.,Rao V. Koneti

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Genetics,Hematology,Molecular Biology

Reference45 articles.

1. A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease;Sneller;J Clin Invest,1992

2. Increases in circulating and lymphoid tissue interleukin-10 in autoimmune lymphoproliferative syndrome are associated with disease expression;Lopatin;Blood,2001

3. Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis;Sneller;Blood,1997

4. Taking ALPS down a Notch;Rao;Blood,2008

5. Autoimmune lymphoproliferative syndrome: a syndrome associated with inherited genetic defects that impair lymphocytic apoptosis—CT and US features;Avila;Radiology,1999

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the epigenome with advanced delivery strategies for epigenetic modulators;Bioengineering & Translational Medicine;2024-08-17

2. Microbiota-derived short-chain fatty acids functions in the biology of B lymphocytes: From differentiation to antibody formation;Biomedicine & Pharmacotherapy;2023-12

3. Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia;Journal for ImmunoTherapy of Cancer;2023-07

4. The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy;Cancer Letters;2023-04

5. Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models;Theranostics;2023